Scenarios that move DHR
Danaher Corporation Common Stock
Scenarios that move DHR: 17 analyses, 15 positive, 2 negative.
- · OPKO Health to sell BioReference assets to Labcorp for $722M — ▲ · impact +12 · confidence low · horizon quarters
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▲ · impact +20 · confidence low · horizon quarters
- · Roche reports positive Phase III eye drug data, FDA accepts BLA — ▲ · impact +17 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▲ · impact +5 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▲ · impact +15 · confidence low · horizon quarters
- · ◇ What if… Plague outbreak in Russia continues and spreads further — ▲ · impact +24 · confidence low · horizon weeks
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▲ · impact +22 · confidence low · horizon quarters
- · Genmab and AbbVie report positive epcoritamab lymphoma trial results — ▲ · impact +10 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▲ · impact +41 · confidence medium · horizon quarters
- · Kodiak Sciences shares soar 178% on positive wet AMD data — ▲ · impact +15 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▲ · impact +14 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▲ · impact +32 · confidence medium · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▲ · impact +8 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▲ · impact +12 · confidence low · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▼ · impact -18 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +25 · confidence low · horizon quarters
- · Sion cuts workforce nearly half after CF study failure — ▼ · impact -10 · confidence low · horizon quarters